BEST of ASCO Portugal 2024 - LM
Abstract
At the 2024 ASCO Conference, several innovative works were presented in the field of Early Breast Cancer, that dive into old and new biomarkers and their potential to inform potential practice changing decisions. This review highlights four of the most relevant presentations in this disease setting.
Downloads
References
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–72.
Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, et al. Prognostic value of the residual cancer burden index according to breast cancer subtype: Validation on a cohort of bc patients treated by neoadjuvant chemotherapy. PLoS One. 2020;15(6 June):1–17.
Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020 Feb;382(9):810–21.
Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (London, England). 2011 Aug;378(9793):771–84.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard J-Y, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol Off J Eur Soc Med Oncol. 2017 Oct;28(10):2340–66.
